• UK Agency Grants Raxone Temporary Approval to Treat Certain DMD Patients
  • Sarepta and Genethon Will Collaborate to Develop DMD Gene Therapy
  • Nuclear Receptor REV-ERB May be Targeted to Improve Muscle Tissue Regeneration Mechanism, Study Finds
  • FDA Grants RASRx1902 Orphan Drug Status as Potential Therapy for Duchenne Muscular Dystrophy
  • Simultaneously Inhibiting Three Proteins Can Increase Muscle Mass in Mice with Muscular Dystrophy, Study Shows
  • June 20, World FSHD Day, Aims to Raise Awareness of Facioscapulohumeral Muscular Dystrophy
  • Former Cancer Therapy Candidate Improves Muscle Function in Duchenne MD Mice
  • SOS Launches DuchenneConnect Australia, Country’s First Patient Registry for DMD Clinical Trials
  • Sarepta Recruits Duchenne Boys for Phase 3 ESSENCE Trial to Test 2 Potential DMD Therapies
  • Gene Therapy Shows Long–Lasting Effects in Animal Model of Myotubular Myopathy
  • Myonexus Launches Development of Gene Therapies Targeting Limb-Girdle MD
  • FDA Advisory Committee to Meet with PTC over Nonsense Mutation DMD Therapy Translarna